DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Uber, Intel, Lyft, Shopify, Rivian and more
▼ + stars: | 2024-05-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

The company's overall revenue exceeded expectations, coming in at $10.13 billion versus analysts' estimate of $10.11 billion, per LSEG. Lyft – The ride-sharing company surged 5% after the company reported faster-than-expected growth in the first quarter. Lyft reported $1.28 billion in revenue, higher than the FactSet consensus of $1.16 billion. Arista Networks – Shares jumped 7% after the company reported better-than-expected first quarter results. Teva Pharmaceuticals — Shares advanced nearly 14% after the company reported better-than-expected revenue in the first quarter.

Persons: Lyft, FactSet, Rivian, Coupang, LSEG, Twilio, –, —, Samantha Subin, Tanaya Macheel, Michelle Fox, Alex Harring Organizations: Technologies, Revenue, LSEG, Intel, Department of Commerce, Huawei, Lyft, Electronic Arts, EA, Farfetch, Arista Networks –, Arista, Dutch Bros, Bros, Pharmaceuticals, Management Locations: China, Korea

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ Teva Pharma CEO Richard Francis on Q4 earnings
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTeva Pharma CEO Richard Francis on Q4 earningsRichard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.

Persons: Richard Francis Organizations: Teva, Teva Pharmaceuticals

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Stocks making the biggest moves midday: United Airlines, TKO Group, 3M, Alibaba and more
▼ + stars: | 2024-01-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +5 min

United Airlines – The airline stock popped nearly 5% a day after the company reported higher-than-expected earnings and revenue for the fourth quarter. TKO Group – Shares of TKO Group Holdings rallied 15.8% after announcing a deal to air its WWE flagship program known as "Raw" on Netflix next year. Revenue topped expectations, but earnings fell 6 cents short of analysts' expectations, per LSEG. Verizon posted $1.08 in adjusted earnings per share on $35.13 billion in revenue, while analysts surveyed by LSEG forecasted $1.07 per share in earnings and $34.64 billion of revenue. Procter & Gamble posted mixed results for its fiscal second quarter , topping earnings expectations but falling short on revenue.

Persons: Alibaba, Alibaba's, Truist, Coinbase – Coinbase, Goldman Sachs, Jefferies, Lockheed Martin, Horton –, Halliburton – Halliburton, Johnson – Johnson, Wall, Gamble, RTX, Zions Bancorporation, Yun Li, Sarah Min, Alex Harring Organizations: United Airlines –, Boeing, Max, Group, WWE, Netflix, LSEG, New York Times, Sunnova Energy, Enphase Energy, Federal Reserve, JPMorgan, Reuters, CSI China Internet, General Electric, GE, Teva Pharmaceutical, Teva Pharmaceuticals, Lockheed, Logitech –, Logitech, Barstool Sports, Johnson, Verizon –, Verizon, Procter, FactSet Locations: Alibaba –, China, fundaments

Tuesday's analyst calls include upgrades to two solar names and a downgrade to a key crypto stock. 7:05 a.m.: Citi increases Meta price target ahead of earnings Meta shares have more runway ahead, according to Citi. Analyst Kenneth Worthington downgraded the crypto exchange to underweight from neutral, reiterating his price target of $80. Analyst Jordan Levy upgraded Sunnova to buy from hold and raised his price target to $18 from $10. He upgraded Enphase Energy to buy from hold, moving his price target to $145 from $85.

Persons: Truist, Ronald Josey, Josey, — Pia Singh, TD Cowen, Jason Gabelman, Gabelman, Jefferies, Glen Santangelo, Teva, Cantor Fitzgerald, C.J, Muse, Kenneth Worthington, Worthington, Coinbase, — Fred Imbert, Jordan Levy, Levy Organizations: CNBC, Enphase Energy, Federal Reserve, JPMorgan, Citi, Meta, Exxon, Chevron, Cowen, Exxon Mobil, Teva Pharmaceuticals, Jefferies Investors, pharma, mdc, Nvidia, Energy, Sustainability Locations: buybacks, Teva, Monday's

☆ Stocks making the biggest moves midday: Foot Locker, Okta, Carnival, Shopify and more
▼ + stars: | 2023-11-27 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Carnival — Shares added 1% after being upgraded to buy from hold by Melius Research . Crown Castle — The telecommunications stock jumped nearly 4% following an activist push for change at Crown Castle. Shares of Crown Castle are down 20% this year. Okta — Shares of the software company dropped 3% Monday after JMP Securities downgraded Okta to market perform. Teva Pharmaceuticals — U.S.-traded shares jumped 3% after an upgrade from UBS to buy from neutral.

Persons: Locker, Josh Weinstein, Melius, Okta, JMP, Albemarle —, Etsy, TD Cowen, —, Alex Harring, Hakyung Kim, Sarah Min, Michelle Fox, Jesse Pound, Darla Mercado Organizations: Citi, Melius Research, Crown, Elliott Investment Management, Sunday, JMP Securities, Albemarle, Battery Tech, U.S, Teva Pharmaceuticals —, UBS, Xenon Pharmaceuticals, —, Adobe Analytics Locations: Crown, Albemarle

☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
▼ + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com time to read: +4 min

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.

Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan

☆ Stocks making the biggest moves midday: Tesla, Nike, Carnival, Nvidia and more
▼ + stars: | 2023-09-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Tesla — Stock in the electric vehicle company added 1.5% in midday trading Friday. Canaccord Genuity reiterated a buy rating on the EV stock on Thursday ahead of vehicle deliveries data. Elsewhere, Citi remained neutral on Tesla and reduced its vehicle delivery forecast to 450,000 from 468,500. Bumble — The online dating platform added 3% after Loop Capital Markets upgraded the stock to buy from hold. Corcept Therapeutics — Shares slumped 17% in midday trading as the firm contends with ongoing litigation against Teva Pharmaceuticals.

Persons: Elon Musk, Canaccord Genuity, Tim Wentworth, Roz Brewer, Bumble —, Cushing, Teva, — CNBC's Pia Singh, Alex Harring, Michelle Fox, Hakyung Kim, Darla Mercado Organizations: U.S, Senate, Intelligence, Capitol, Washington , D.C, Citi, Barclays, Anheuser, Busch InBev — U.S, LSEG, Cruise, Wonder Group, Nvidia —, Blackwell, Nvidia, Nike —, Nike, Walgreens, Bloomberg, Therapeutics, Teva Pharmaceuticals, Texas, Northcoast Research Locations: Washington ,

☆ Amoxicillin shortage: A new season of infections is here, but the shortage of a common kids’ antibiotic never ended
▼ + stars: | 2023-09-22 | by ( Brenda Goodman | ) edition.cnn.com time to read: +7 min

Respiratory illness season is coming up, and that’s going to be a huge issue,” said David Margraf, a pharmaceutical research scientist with the University of Minnesota’s Resilient Drug Supply Project. During a drug shortage, allocation helps ensure that no single buyer can claim all the available supply. Khazanchi and his colleague Dr. Ryan Brewster recently studied the clinical effects of last winter’s amoxicillin shortage. “Drug shortages will likely continue to increase if the pricing dynamics in the marketplace are not addressed,” Sandoz said in a statement. “The companies refuse to tell us what’s going on,” said Erin Fox, who tracks drug shortages at the University of Utah.

Persons: —, earaches, ”, David Margraf, Selena Ko, Erin Hooley, pediatricians, Rohan Khazanchi, Khazanchi, Ryan Brewster, Amoxicillin, ” Khazanchi, “ It’s, ” Sandoz, Erin Fox, Laura Bray, They’re, ” Margraf, ” Bray, Dr, Sanjay Gupta, “, Matt Christian Organizations: CNN, Food, University of, Project, Rush University Medical Center, Chicago Tribune, TNS, Getty, FDA, Brigham & Women’s Hospital, Teva Pharmaceuticals, Novartis, University of Utah, Angels, CNN Health, US Department of Agriculture, Pharmacopeia’s Medicines Locations: Chicago, Boston

☆ The ADHD drug market is already stretched thin. Now it's facing a back-to-school supply strain
▼ + stars: | 2023-08-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc. Adderall and alternative ADHD medications apart from other drugs are Schedule 2 controlled substances. Production limitationsEnding the shortages of Adderall and other ADHD medications is no easy task. That means increasing the production of one drug could potentially require reducing production — and potentially impacting supply — of another drug, according to Ergun. That includes Aytu BioPharma, which makes an ADHD drug that used to be in shortage.

Persons: Jb Reed, It's, Erin Fox, they've, David Margraf, Margraf, drugmakers, Ozlem Ergun, Ergun, Novartis's, Michael Ganio, ASHP's Ganio, RJ Sangosti, Josh Disbrow, Fox Organizations: Shire Plc, Jb, Bloomberg, Getty, and Drug Administration, CNBC, University of Utah, American Society of Health, System Pharmacists, Centers for Disease Control, University of Minnesota's, Infectious Disease, Northeastern University, Teva Pharmaceuticals, Amneal Pharmaceuticals, Sandoz, Purdue Pharma, Rhodes Pharmaceuticals, Drug, Fox, Pharmacists, Drug Enforcement Administration, MediaNews, Denver, FDA, DEA Locations: U.S, Commerce City , Colorado

☆ Teva Pharmaceuticals to pay $225 mln to settle price-fixing charges
▼ + stars: | 2023-08-21 | by ( ) www.reuters.com time to read: 1 min

The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen/File Photo Acquire Licensing RightsAug 21 (Reuters) - Teva Pharmaceuticals will pay a fine of $225 million over five years to settle the criminal price-fixing charges brought against Teva in 2020 by the U.S. Department of Justice, the company said on Monday. Reporting by Pratik Jain in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: Amir Cohen, Pratik Jain, Shailesh Organizations: Teva Pharmaceutical Industries, REUTERS, Teva Pharmaceuticals, Teva, U.S . Department of Justice, Thomson Locations: Tel Aviv, Israel, Bengaluru

☆ Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges
▼ + stars: | 2023-08-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Drugmaker Teva Pharmaceuticals agreed to pay $225 million in criminal fines over five years and divest its version of a generic cholesterol drug to resolve charges related to price-fixing on that medication and other widely used treatments, the Department of Justice announced Monday. Teva, in a press release Monday, said it will pay $22.5 million each year from 2024 through 2027, and $135 million in 2028. Glenmark Pharmaceuticals will pay $30 million to resolve similar charges. Since 2020, the DOJ's antitrust division has charged five other pharmaceutical companies for participating in similar schemes affecting several generic drugs. Teva has also agreed to donate $50 million worth of two generic drugs affected by price-fixing to humanitarian organizations that provide medications to Americans in need.

Persons: Drugmaker, Teva, Jonathan Kanter, Glenmark, Apotex Organizations: Drugmaker Teva Pharmaceuticals, Department of Justice, Glenmark Pharmaceuticals, Antitrust Division, DOJ, Eastern District of Pennsylvania, Apotex Corp Locations: Eastern District

☆ Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges
▼ + stars: | 2023-08-21 | by ( Ramishah Maruf | ) edition.cnn.com time to read: +3 min

New York CNN —Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency announced Monday. The core drug involved and that will be divested to a third party was pravastatin, a widely used cholesterol medication. Teva’s rival Glenmark will also pay a $30 million criminal penalty to be paid in six installments, the company said. In a statement, Teva said it will pay $225 million over the course of five years. As part of the agreement, Teva admitted to participating in the three conspiracies, the DOJ said.

Persons: Glenmark, Sanjeev Krishan, “, Teva, ”, Jonathan Kanter, ” Teva Organizations: New, New York CNN, Teva Pharmaceuticals, US Department of Justice, DOJ, “ Companies Locations: New York

☆ A son died, his parents tried to sue. How U.S. courts protect Big Pharma
▼ + stars: | 2023-06-26 | by ( ) www.reuters.com time to read: +26 min

His parents soon started exploring a lawsuit against Merck, the developer of the blockbuster asthma and allergy drug, Singulair, along with the manufacturer of the generic version their son took. That meant Merck had written the warning label, with federal approval, on the generic version of Singulair that Nicholas England took. But his parents couldn’t sue Merck, either, because their son had never taken its name-brand version of Singulair. The generic drug manufacturer that made the pills England took, Teva Pharmaceuticals, did not respond to inquiries. Since Merck’s patent on Singulair expired in 2012, major generic drug manufacturers have sold millions of prescriptions under the drug’s scientific name, montelukast.

Persons: Nicholas England, Nicholas, Merck, ”, Jennifer England, Nicholas’s, ” Merck, Organon, “, George W, Bush, Daniel Troy, Troy, Medtronic, Nicholas England’s, Adam Zimmerman, ” Zimmerman, Jay Lefkowitz, Ellis, shouldn’t, Bayer, drugmaker Wyeth, Phenegran, Jan Gilpin’s, mumbling, ” Gilpin, ” “, hadn’t, Singulair, Gilpin, Stephane Bissonnette, suicidality, Dr, Judith Kramer, Duke, Robert England, Robert said, Kim Beck Organizations: Merck, U.S, Teva Pharmaceuticals, Reuters, U.S . Food, Drug Administration, FDA, Big, Corporate America, Corporations, Administration, ”, New, University of Southern California’s Gould School of Law, Norfolk, Union Pacific, Federal Railroad Safety, Pacific, GlaxoSmithKline, Monsanto, Bayer, Parent Locations: Virginia, England, U.S, New York, Kirkland, East Palestine , Ohio, Louisiana, Atlanta, Vermont, Wise , Virginia, Wisconsin

☆ Here are Thursday's biggest analyst calls: Tesla, Amazon, Netflix, Walmart, Nvidia, FedEx, Meta & more
▼ + stars: | 2023-05-18 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Citi names Meta top pick Citi said Meta is its new top pick pick based on the strength of its ad platforms. Jefferies reiterates Amazon as buy Jefferies said it sees a "strong AI opportunity" for the e-commerce giant. " "We believe upcoming results from FedEx next month can be a meaningful positive catalyst for shares. Citi reiterates Tesla as neutral Citi said its recent survey checks show Tesla has an "impressive loyalty lead." Jefferies reiterates Walmart as buy Jefferies said the big box giant is still a top pick after its robust earnings report on Thursday morning. "

Organizations: ~$

Such "skinny labels" typically allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents. GSK sued Teva for patent infringement in Delaware federal court in 2014 over its generic version of Coreg. In its petition to the Supreme Court last year, Teva said the ruling would cause "havoc" for skinny labels, which it said are "extraordinarily common" and "save patients and the federal government billions." GSK countered that the case does not threaten generic drugmakers that "operate properly under the law." The Biden Administration backed Teva on Wednesday, arguing generic drugmakers should be entitled to rely on the FDA's carve-out instructions, which are based on brand-name drugmakers' own statements to the agency.

☆ US FDA approves first OTC opioid overdose reversal drug
▼ + stars: | 2023-03-29 | by ( ) www.reuters.com time to read: +2 min

[1/2] A box of NARCAN nasal spray is photographed at an outpatient treatment center in Indiana, Pennsylvania, U.S. on August 9, 2017. The approval for OTC use of the naloxone-based nasal spray will help align the federal government's stance with states that have provisions to offer the drug without prescription at pharmacies. Drug-related overdose deaths in the United States rose about 15% year-over-year to more than 100,000 in 2021, as per official data. While the approval puts Emergent ahead in the OTC product race, analysts have said it is not likely to derive significant sales from the approval. Benchmark analyst Robert Wasserman said ahead of the approval that Narcan sales peaked in 2020 and have declined since.

Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. European generic drugmakers say the tender system and regulated prices have fuelled a race to the bottom, and European firms are being undercut by suppliers from Asia. BRUSSELS, WE HAVE A PROBLEMThe European Medicines Agency (EMA) and European Union lawmakers acknowledge there is a problem. Half the generic medicines sold in Spain are priced below 1.60 euros per box or bottle, the country's generics manufacturing association said. But companies with smaller market shares, such as Israel's Teva (TEVA.TA), which has 5% of the region's amoxicillin market according to Medicines for Europe, are constrained.

☆ Adderall users struggle amid ongoing medication shortage
▼ + stars: | 2022-11-17 | by ( Raenu Charles | ) edition.cnn.com time to read: +7 min

A report from data analytics firm Trilliant Health found that nationally, prescriptions for Adderall among people ages 22 to 44 increased 15% between 2020 and 2021. “I’ve had patients call 10,15, 20 pharmacies in order to get their medication,” Goodman said. Clara is headed to her doctor to seek an alternative medication until Adderall is back in stock. It took five days for his pharmacy to fill his prescription in late October, and those days took a toll. Goodman strongly warns against this, offering a reminder that not only is selling your own prescription medication a felony, so is sharing it with others.

☆ Opioid settlement: Walmart agrees to $3.1 billion framework
▼ + stars: | 2022-11-15 | by ( Kristina Sgueglia | ) edition.cnn.com time to read: +2 min

New York CNN Business —Walmart agreed to the framework of a $3.1 billion settlement, which resolves allegations from multiple states’ attorneys general that the company failed to regulate opioid prescriptions contributing to the nationwide opioid crisis. The framework will resolve virtually all opioid lawsuits and potential lawsuits by state, local, and tribal governments against Walmart, assuming all the settlement’s conditions are satisfied. As part of the framework of the agreement, New York state will receive up to $116 million. The settlement is still pending approval from other states, but James’ office believes they will give the deal their blessing by the end of the year. “Promising negotiations,” are still underway with other pharmacies including Walgreens and CVS, James’ office said.

☆ Three-Stock Lunch: AMD, HAS & TEVA
▼ + stars: | 2022-11-14 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThree-Stock Lunch: AMD, HAS & TEVACraig Johnson, chief market technician at Piper Sandler, joins 'Power Lunch' to offer his picks for today's three-stock lunch, looking at the technicals of Advanced Micro, Hasbro and Teva Pharmaceuticals.

Nov 9 (Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday. The jury agreed with Teva that Lilly's Emgality violated its rights in the patents, which relate to its own migraine drug Ajovy. Teva sued Lilly over the patents in 2018. The same day Teva sued, the court dismissed two related Teva lawsuits seeking to block Emgality from coming onto the U.S. market. Teva also filed a separate, ongoing patent lawsuit against Lilly in Massachusetts over Emgality last year.

Companies Teva Pharmaceutical Industries Ltd FollowNov 3 (Reuters) - Teva Pharmaceuticals (TEVA.TA) will pay up to $4.2 billion in the United States to settle claims related to its role in fueling the country's opioid crisis, New York Attorney General Letitia James said on Thursday. The company will pay $523 million to New York state to settle claims in the state, James said. Reporting by Leroy Leo in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

The Food and Drug Administration on Wednesday confirmed a nationwide shortage of the attention-deficit/hyperactivity disorder medication Adderall, more than two months after some pharmacies reported difficulties filling prescriptions. The shortage affects the immediate-release form of Adderall, a stimulant that helps manage ADHD symptoms. Dougherty added that Teva expects “intermittent delays through end of year.”The supply from the other Adderall manufacturers isn’t enough to meet the need, the FDA said. The shortage has hit pharmacies differentlySome pharmacies have been having trouble filling Adderall prescriptions since the summer. In May, Walmart and CVS announced they would stop filling prescriptions for controlled substances from telehealth startups such as Cerebral and Done Health, which prescribe stimulants and gained footing during the pandemic.

Search resuls for: "Teva Pharmaceuticals"

25 mentions found